VTRS

0.08% -0.010

Dopo l'orario di chiusura: 11.91 -0.02 -0.17%

Viatris Inc (VTRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1134)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Prossima data di guadagno

Ultimi documenti SEC

VTRS's Discussions on Twitter

Confronta VTRS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTRS Viatris Inc	11.93	13.75B	14.33B	-3.79B	1.84B	-3.17
ZTS Zoetis Inc	122.24	54.10B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.90	46.85B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.90	43.82B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	30.35	34.79B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	517.13	21.83B	3.08B	1.24B	1.07B	25.61

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Barclays	Overweight
2025-10-15	Iniziato	Truist	Buy
2025-06-06	Iniziato	Goldman	Neutral
2024-07-19	Ripresa	Jefferies	Buy
2023-10-23	Downgrade	BofA Securities	Neutral → Underperform
2023-06-23	Downgrade	Barclays	Equal Weight → Underweight
2023-04-24	Downgrade	Barclays	Overweight → Equal Weight
2023-02-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Aggiornamento	Jefferies	Hold → Buy
2022-11-10	Aggiornamento	UBS	Sell → Neutral
2022-11-08	Aggiornamento	Piper Sandler	Underweight → Neutral
2022-10-21	Ripresa	Jefferies	Hold
2022-06-14	Iniziato	UBS	Sell
2022-05-10	Downgrade	Piper Sandler	Neutral → Underweight
2022-03-01	Downgrade	BofA Securities	Buy → Neutral
2022-03-01	Downgrade	Raymond James	Outperform → Mkt Perform
2021-06-15	Iniziato	Citigroup	Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-03-08	Downgrade	Goldman	Buy → Neutral
2021-03-02	Downgrade	JP Morgan	Overweight → Neutral
2021-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2021-01-05	Iniziato	Argus	Hold
2020-12-14	Iniziato	Bernstein	Mkt Perform

Mostra tutto

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris Inc Azioni (VTRS) Dati Finanziari

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Confronta VTRS con altri titoli

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Borsa (VTRS) Ultime notizie

Is Viatris stock outperforming the Dow? - MSN

Wall Street Recap: How strong is Viatris Inc. stock revenue growthStock Surge & Safe Capital Growth Trade Ideas - moha.gov.vn

Why Viatris Inc. stock remains on buy listsWeekly Gains Summary & Safe Entry Momentum Stock Tips - Bölüm Sonu Canavarı

Earnings Risk: How Viatris Inc. (VIA) stock trades after earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru

Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS? - Yahoo Finance

Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment - Yahoo Finance

Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks

Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates - Yahoo News Malaysia

Is Viatris Inc. stock safe for conservative investorsEarnings Miss & Fast Moving Stock Watchlists - DonanımHaber

Viatris’ MR-146 gains IND clearance for neurotrophic keratopathy - BioWorld MedTech

Will Viatris Inc. stock outperform Nasdaq index2025 Valuation Update & Verified Technical Trade Signals - DonanımHaber

Update Recap: How Viatris Inc. stock valuations compare to rivalsWeekly Market Report & Fast Entry Momentum Alerts - Улправда

Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com

Viatris racks up regulatory wins across therapy areas - The Pharma Letter

Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials - marketscreener.com

Rally Mode: How Viatris Inc VIA stock behaves in tightening cyclesQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - moha.gov.vn

Viatris secures four regulatory milestones across global pipeline - Investing.com

Viatris provides pipeline update on four regulatory milestones - marketscreener.com

Viatris Provides Pipeline Update On Four Regulatory Milestones - TradingView — Track All Markets

New gene therapy and weekly birth control patch move forward at Viatris - Stock Titan

Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Does Viatris’ Reshaping Strategy Make Sense After Recent Share Price Swings? - Yahoo Finance

Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back - The Globe and Mail

Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., - PharmiWeb.com

Is Viatris Stock Outperforming the Dow? - Barchart.com

Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - 28/22 News

Non-operating income (total) of Viatris, Inc. – SIX:VTRS.USD - TradingView — Track All Markets

Risk Analysis: How Viatris Inc VIA stock behaves in tightening cyclesJuly 2025 Snapshot & Verified Swing Trading Watchlist - moha.gov.vn

Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com

Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus

How Viatris Inc stock reacts to global recession fearsJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn

Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare

Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq

Barclays Initiates Viatris at Overweight With $15 Price Target - marketscreener.com

Viatris to sell equity stake in Biocon Biologics to Biocon for $815M - MSN

Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com

CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench

Viatris signs agreements with Biocon on $815m stake sale - MSN

Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛

Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks

Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView — Track All Markets

Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN

Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com

Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha

Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln - Nasdaq

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - Prime Publishers, Inc.

Biocon To Absorb Biocon Biologics, Pursue Rs 4,500 Cr QIP To Fund Viatris Payout - BW Businessworld

Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake - Moneycontrol

Biocon integrates Biocon Biologics; to raise ₹4,500 crore via QIP to fund Viatris payout - BusinessLine

Viatris Inc Azioni (VTRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a VTRS